Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 2
2008 2
2009 3
2010 5
2011 5
2012 4
2013 5
2014 6
2015 4
2016 8
2017 9
2018 6
2019 2
2020 5
2021 8
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: nayak tk. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Among authors: nayak t. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
Implementing liquid biopsies into clinical decision making for cancer immunotherapy.
Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B. Quandt D, et al. Among authors: nayak t. Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Oncotarget. 2017. PMID: 28501851 Free PMC article. Review.
Mechanistic Basis for Maximally Efficacious Dose of Pembrolizumab.
Mayawala K, Nayak T, Jain L, de Alwis D. Mayawala K, et al. Among authors: nayak t. Clin Pharmacol Ther. 2022 May;111(5):994. doi: 10.1002/cpt.2492. Epub 2021 Dec 3. Clin Pharmacol Ther. 2022. PMID: 34859427 No abstract available.
PET imaging to monitor cancer therapy.
Malviya G, Nayak TK. Malviya G, et al. Among authors: nayak tk. Curr Pharm Biotechnol. 2013;14(7):669-82. doi: 10.2174/1389201014666131226104750. Curr Pharm Biotechnol. 2013. PMID: 24372238 Review.
Cyclic activation of endplate acetylcholine receptors.
Nayak TK, Auerbach A. Nayak TK, et al. Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):11914-11919. doi: 10.1073/pnas.1711228114. Epub 2017 Oct 23. Proc Natl Acad Sci U S A. 2017. PMID: 29078356 Free PMC article.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Stathis A, Tolcher AW, Wang JS, Renouf DJ, Chen LC, Suttner LH, Freshwater T, Webber AL, Nayak T, Siu LL. Stathis A, et al. Among authors: nayak t. Invest New Drugs. 2023 Jun;41(3):380-390. doi: 10.1007/s10637-022-01326-3. Epub 2023 Apr 11. Invest New Drugs. 2023. PMID: 37040046 Free PMC article. Clinical Trial.
Neural inference at the frontier of energy, space, and time.
Modha DS, Akopyan F, Andreopoulos A, Appuswamy R, Arthur JV, Cassidy AS, Datta P, DeBole MV, Esser SK, Otero CO, Sawada J, Taba B, Amir A, Bablani D, Carlson PJ, Flickner MD, Gandhasri R, Garreau GJ, Ito M, Klamo JL, Kusnitz JA, McClatchey NJ, McKinstry JL, Nakamura Y, Nayak TK, Risk WP, Schleupen K, Shaw B, Sivagnaname J, Smith DF, Terrizzano I, Ueda T. Modha DS, et al. Among authors: nayak tk. Science. 2023 Oct 20;382(6668):329-335. doi: 10.1126/science.adh1174. Epub 2023 Oct 19. Science. 2023. PMID: 37856600
77 results